uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Early Discontinuation of Metformin in Individuals Treated with Inhibitors of Transporters of Metformin
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences. Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol, JB Winslows Vej 19,2, DK-5000 Odense C, Denmark..
Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA USA..
Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol, JB Winslows Vej 19,2, DK-5000 Odense C, Denmark..
Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol, JB Winslows Vej 19,2, DK-5000 Odense C, Denmark..
Show others and affiliations
2016 (English)In: Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, E-ISSN 1742-7843, Vol. 118, no 6, 487-495 p.Article in journal (Refereed) PublishedText
Abstract [en]

The aim of this study was to examine the risk of early discontinuation of metformin as a proxy for intolerance, associated with use of drugs known to inhibit transporters involved in metformin distribution. We analysed all incident users of metformin in Denmark between 2000 and 2012 (n = 132,221) and in a cohort of US patients (n = 296,903). Risk of early discontinuation of metformin was assessed using adjusted logistic regression for 28 drugs putatively inhibiting metformin transporters and four negative controls. Increased odds ratio of early discontinuation of metformin was only associated with codeine, an inhibitor of organic cation transporter 1 in both cohorts [adjusted odds ratio (OR) in Danish cohort (95% CI): 1.13 (1.021.26), adjusted OR in American cohort (95% CI): 1.32 (1.19-1.47)]. The remaining drugs were not associated with increased odds ratio of early discontinuation and, surprisingly, four drugs were associated with a decreased risk. These findings indicate that codeine use may be associated with risk of early discontinuation of metformin and could be used as a basis for further investigation.

Place, publisher, year, edition, pages
2016. Vol. 118, no 6, 487-495 p.
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-299901DOI: 10.1111/bcpt.12579ISI: 000378419200013PubMedID: 27128732OAI: oai:DiVA.org:uu-299901DiVA: diva2:950376
Funder
AstraZeneca
Available from: 2016-07-29 Created: 2016-07-29 Last updated: 2016-07-29Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Basic & Clinical Pharmacology & Toxicology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 6 hits
ReferencesLink to record
Permanent link

Direct link